Charles Schwab
VIR icon

Charles Schwab’s Vir Biotechnology VIR Stock Holding History

Charles Schwab’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.5M Buy
1,323,185
+151,501
+13% +$1.44M ﹤0.01% 2021
2026
Q1 		$10.5M Buy
1,171,684
+267,204
+30% +$2.13M ﹤0.01% 2075
2025
Q4 		$5.45M Sell
904,480
-238,399
-21% -$1.42M ﹤0.01% 2408
2025
Q3 		$6.53M Sell
1,142,879
-150,137
-12% -$768K ﹤0.01% 2312
2025
Q2 		$6.52M Sell
1,293,016
-81,858
-6% -$439K ﹤0.01% 2220
2025
Q1 		$8.91M Buy
1,374,874
+122,219
+10% +$1.09M ﹤0.01% 2004
2024
Q4 		$9.19M Buy
1,252,655
+118,379
+10% +$934K ﹤0.01% 2054
2024
Q3 		$8.5M Buy
1,134,276
+136,087
+14% +$1.18M ﹤0.01% 2109
2024
Q2 		$8.88M Buy
998,189
+168,878
+20% +$1.62M ﹤0.01% 2102
2024
Q1 		$8.4M Buy
829,311
+76,238
+10% +$776K ﹤0.01% 2071
2023
Q4 		$7.58M Buy
753,073
+31,405
+4% +$287K ﹤0.01% 2135
2023
Q3 		$6.76M Buy
721,668
+84,694
+13% +$1.21M ﹤0.01% 2115
2023
Q2 		$15.6M Buy
636,974
+26,817
+4% +$673K ﹤0.01% 1666
2023
Q1 		$14.2M Sell
610,157
-124,590
-17% -$3.19M ﹤0.01% 1700
2022
Q4 		$18.6M Buy
734,747
+83,374
+13% +$2.04M 0.01% 1500
2022
Q3 		$12.6M Sell
651,373
-118,191
-15% -$3M ﹤0.01% 1687
2022
Q2 		$19.6M Buy
769,564
+24,236
+3% +$566K 0.01% 1424
2022
Q1 		$19.2M Buy
745,328
+18,792
+3% +$557K 0.01% 1584
2021
Q4 		$30.4M Buy
726,536
+27,892
+4% +$1.09M 0.01% 1255
2021
Q3 		$30.4M Buy
698,644
+110,188
+19% +$4.77M 0.01% 1216
2021
Q2 		$27.8M Buy
588,456
+31,284
+6% +$1.42M 0.01% 1311
2021
Q1 		$28.6M Buy
557,172
+14,801
+3% +$798K 0.01% 1226
2020
Q4 		$14.5M Buy
542,371
+5,936
+1% +$193K 0.01% 1627
2020
Q3 		$18.4M Buy
536,435
+435,872
+433% +$18.8M 0.01% 1256
2020
Q2 		$4.12M Buy
100,563
+85,366
+562% +$2.87M ﹤0.01% 2114
2020
Q1 		$521K Sell
15,197
-269
-2% -$7.23K ﹤0.01% 2702
2019
Q4 		$195K Buy
+15,466
New +$207K ﹤0.01% 3042

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Charles Schwab's VIR Position: Q2 2026 in Review

Charles Schwab increased its Vir Biotechnology (VIR) stake by 13% in Q2 2026, buying an estimated $1.44M and bringing the position to 1,323,185 shares worth $13.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2021.

Charles Schwab first reported a position in VIR in Q4 2019 and has held it in 27 quarters since. The position peaked at $30.4M in Q4 2021. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Charles Schwab held 1,323,185 shares of Vir Biotechnology worth $13.5M as of Q2 2026.
  • Charles Schwab bought 151,501 Vir Biotechnology shares in Q2 2026, an estimated $1.44M.
  • Vir Biotechnology made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2021 holding.
  • Charles Schwab first reported a position in Vir Biotechnology in Q4 2019 and has held it in 27 quarters since.
  • Charles Schwab's Vir Biotechnology position peaked at $30.4M in Q4 2021.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.